JPT Peptide Technologies GmbH (JPT), a wholly-owned subsidiary of Jerini AG (FSE: JI4), and Mount Sinai School of Medicine (MSSM) announced today their collaboration on the discovery of B-cell epitopes, aimed at accelerating the development of vaccines and personalized diagnostics in the field of food allergies. This collaboration combines MSSM's proven track record of identifying and deciphering relevant food allergens with JPT's proprietary PepStarTM peptide-microarray platform, which produces complex peptide microarrays that scan diverse protein antigens and entire proteoms.
